Document Detail


A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
MedLine Citation:
PMID:  11365999     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Some physicians are beginning to prescribe potent drug cocktails that do not include protease inhibitors. This is a departure from the standard treatment that has included protease inhibitors since their introduction in recent years. Protease inhibitors remain among the most effective and important treatments developed, but there are significant problems, including cross-resistance and patient intolerance. Also, protease inhibitors are associated with serious side effects such as lipodystrophy. Protease-sparing regimens such as abacavir/AZT/3TC and drug combinations that include efavirenz appear to be as effective as protease-inhibitor containing regimens. Results of new treatment approaches are summarized.
Authors:
L Hanna
Related Documents :
16346379 - Production and characteristics of raw starch-digesting glucoamylase o from a protease-n...
7791959 - Characterization of a serine peptidase responsible for the inactivation of endogenous c...
1993059 - Salivary histatin as an inhibitor of a protease produced by the oral bacterium bacteroi...
19013149 - The role of protease activity in erbb biology.
20704569 - Structural and mechanistic insight into how antibodies inhibit serine proteases.
12784999 - Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolyt...
25147609 - Conformationally restricted gaba with bicyclo[3.1.0]hexane backbone as the first highly...
22984809 - Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of i...
660589 - Inactivation of trypsin-like proteases by sulfonylation. variation of positively charge...
Publication Detail:
Type:  Newspaper Article    
Journal Detail:
Title:  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation     Volume:  -     ISSN:  1058-708X     ISO Abbreviation:  BETA     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-10-08     Completed Date:  1999-10-08     Revised Date:  2014-08-25    
Medline Journal Info:
Nlm Unique ID:  9113964     Medline TA:  BETA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  9-13     Citation Subset:  X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / therapeutic use*
Antineoplastic Agents / therapeutic use*
Benzoxazines
Clinical Trials as Topic
Dideoxynucleosides / therapeutic use
Drug Resistance, Microbial
Drug Therapy, Combination
Drugs, Investigational
HIV Infections / drug therapy*
HIV Protease Inhibitors / adverse effects*,  pharmacology
Humans
Hydroxyurea / therapeutic use*
Lamivudine / therapeutic use
Lipodystrophy / chemically induced*
Oxazines / therapeutic use*
Reverse Transcriptase Inhibitors / therapeutic use*
Time Factors
Zidovudine / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Antineoplastic Agents; 0/Benzoxazines; 0/Dideoxynucleosides; 0/Drugs, Investigational; 0/HIV Protease Inhibitors; 0/Oxazines; 0/Reverse Transcriptase Inhibitors; 2T8Q726O95/Lamivudine; 4B9XT59T7S/Zidovudine; JE6H2O27P8/efavirenz; WR2TIP26VS/abacavir; X6Q56QN5QC/Hydroxyurea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ABT-378: a second generation protease inhibitor.
Next Document:  Appeals court set to re-examine dental bias case.